Rezdiffra (Resmetirom) Cost in Utah 2026: Pricing, Insurance, and Savings Options

What Rezdiffra Costs at Utah Pharmacies in 2026

The retail price for Rezdiffra in Utah sits at approximately $3,500 per month, matching Madrigal Pharmaceuticals' national list price [1]. That figure applies whether you fill at a Walgreens in Salt Lake City, a Harmons pharmacy in Provo, or an independent pharmacy in St. George. Cash-pay pricing shows almost no regional variation across the state because Rezdiffra remains a single-source branded product with no generic equivalent available.

Your actual out-of-pocket cost depends on three variables: your insurance formulary tier, whether prior authorization is approved, and whether you qualify for the manufacturer's copay assistance program. Patients with no insurance coverage and no copay assistance face the full $3,500 monthly charge. That adds up to $42,000 per year for a drug intended as long-term therapy.

Rezdiffra is dosed as a once-daily oral tablet. Patients weighing less than 100 kg receive the 80 mg dose, while those at or above 100 kg take 100 mg [2]. Both strengths carry the same list price in Utah. The FDA approved resmetirom in March 2024, making it the first drug specifically indicated for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced hepatic fibrosis, stages F2 and F3 [2]. Before this approval, no pharmacotherapy carried an FDA indication for MASH, a disease affecting an estimated 6 to 8 million Americans with significant fibrosis [3].

Utah Medicaid Does Not Cover Rezdiffra

Utah Medicaid does not include Rezdiffra on its preferred drug list as of 2026. Patients enrolled in traditional Medicaid or Utah's Medicaid expansion (enacted in 2020) cannot obtain coverage for resmetirom through the state program. This exclusion affects a substantial population: roughly 450,000 Utahns receive Medicaid benefits.

The absence of Medicaid coverage is not unique to Utah. Most state Medicaid programs have been slow to add Rezdiffra to formularies, largely because of cost concerns and the requirement for liver biopsy or validated noninvasive testing to confirm fibrosis staging. The Endocrine Society's 2024 clinical practice guideline on MASH pharmacotherapy noted that "payer coverage decisions will determine real-world access to resmetirom for the patients most likely to benefit" [4].

For Utah Medicaid enrollees, options remain limited. You can request a coverage exception through a prior authorization appeal, though approval rates for non-formulary specialty drugs in Utah Medicaid historically run below 20%. Alternatively, the Madrigal patient assistance program may provide Rezdiffra at no cost to uninsured or underinsured patients who meet income thresholds (generally household income at or below 400% of the federal poverty level).

Commercial Insurance Coverage in Utah

Most large commercial insurers operating in Utah, including SelectHealth, Regence BlueCross BlueShield, DMBA, Cigna, and UnitedHealthcare, have added Rezdiffra to specialty tier formularies with prior authorization requirements. Approval typically requires documentation of three things: a confirmed MASH diagnosis, fibrosis staged at F2 or F3 by liver biopsy or validated noninvasive composite score (such as FibroScan with an LSM of 8.0 kPa or higher plus an NFS or FIB-4 in the intermediate-to-high range), and evidence that the patient has attempted lifestyle modification for at least 6 months [2].

Once approved, Rezdiffra usually lands on a specialty tier (Tier 4 or Tier 5), producing coinsurance rates of 25% to 50%. Without the savings card, that means monthly out-of-pocket costs between $875 and $1,750. Specialty copay accumulators, which some Utah plans use, can prevent manufacturer copay card payments from counting toward your annual out-of-pocket maximum. Check your plan's accumulator policy before assuming the savings card will carry you through the benefit year.

Dr. Mary Rinella, a hepatologist at the University of Chicago and lead author on AGA clinical guidance for MASH, stated in 2024: "The prior authorization process for resmetirom needs to balance cost containment with the clinical urgency of treating patients whose fibrosis is progressing toward cirrhosis" [5]. That tension plays out daily in Utah, where specialty pharmacy benefit managers control the gateway to approval.

How the Madrigal Savings Card Works in Utah

Madrigal Pharmaceuticals offers a copay assistance program that can reduce out-of-pocket costs to $0 per month for eligible patients. The card is valid at all Utah pharmacies that dispense Rezdiffra, including specialty pharmacies.

Eligibility requires commercial insurance coverage for Rezdiffra. Patients on Medicare Part D, Medicaid, TRICARE, or other government-funded programs do not qualify for the savings card (this is a federal anti-kickback statute restriction, not a Madrigal policy choice). The card covers up to $13 to 000 in annual copay or coinsurance costs. For most commercially insured Utah patients whose plan approves Rezdiffra, that cap is sufficient to bring 12 months of out-of-pocket costs to zero.

To activate the card, visit the Madrigal Rezdiffra website or call their patient support line. Your prescribing physician's office can also initiate enrollment. Processing takes 3 to 5 business days. The card must be presented at each fill; it functions as a secondary payer, covering the gap between what your insurance pays and the pharmacy's charge.

One wrinkle for Utah patients: if your plan uses a copay accumulator or maximizer program, the savings card payments may not reduce your deductible or out-of-pocket maximum. Plans offered through large employers in Utah's tech corridor (particularly self-funded plans administered by Cigna or Aetna) increasingly use these accumulator designs. Ask your benefits coordinator directly whether manufacturer copay assistance counts toward your accumulator.

Compounded Resmetirom in Utah: Legal but Limited

Utah permits 503A compounding pharmacies to prepare resmetirom formulations. This is legal under both federal law (FDCA Section 503A) and Utah Code 58-17b, which regulates pharmacy compounding within the state. A 503A pharmacy may compound resmetirom for an individual patient with a valid prescription, provided the pharmacy does not produce the compound in anticipation of receiving prescriptions (no "office stock" batches).

The practical reality is more complicated. Resmetirom's active pharmaceutical ingredient (API) is not widely available from FDA-registered bulk suppliers. Only a small number of 503A pharmacies in Utah currently source the raw material, and pricing, quality assurance, and bioequivalence testing vary. Compounded resmetirom has not undergone the same dissolution and bioavailability studies that the FDA required for Rezdiffra's NDA approval [2]. The FDA's guidance on compounding emphasizes that compounded drugs are not FDA-approved and do not carry the same safety and efficacy data as their branded counterparts [6].

For patients considering compounded resmetirom in Utah, ask the pharmacy three questions: Where is the API sourced? Does the pharmacy hold current USP 795/800 compliance? Has the finished preparation been tested by a third-party lab for potency and purity? A compounding pharmacy that cannot answer all three is not one you should trust with a drug you plan to take daily for years.

Rezdiffra via Telehealth in Utah

Utah law permits telehealth prescribing of Rezdiffra. The state adopted permanent telehealth parity legislation in 2021, requiring insurers to cover telehealth visits at the same rate as in-person encounters. A physician licensed in Utah can evaluate you remotely, review your labs and imaging, and prescribe resmetirom if clinically appropriate [7].

This matters for patients in rural Utah. The state's hepatology specialists concentrate in the Wasatch Front corridor (Salt Lake City, Provo, Ogden). Patients in counties like San Juan, Grand, or Garfield face drives of 4 to 6 hours to reach a liver specialist in person. Telehealth removes that barrier for follow-up visits, though most hepatologists still require at least one in-person evaluation with FibroScan or biopsy before initiating therapy.

HealthRX offers telehealth consultations with physicians experienced in MASH treatment. If you have recent labs (including ALT, AST, and lipid panel) and fibrosis staging results, a telehealth provider can determine whether Rezdiffra is appropriate and submit the prior authorization to your insurance. Specialty pharmacy delivery operates statewide in Utah, so the medication ships directly to your door regardless of ZIP code.

Clinical Evidence Behind Rezdiffra

Rezdiffra's approval rested primarily on the MAESTRO-NASH trial, a Phase 3, randomized, double-blind, placebo-controlled study published in the New England Journal of Medicine in February 2024 [8]. The trial enrolled 966 patients with biopsy-confirmed MASH and fibrosis stages F1B through F3. At 52 weeks, 25.9% of patients receiving resmetirom 80 mg and 29.9% receiving 100 mg achieved MASH resolution with no worsening of fibrosis, compared to 9.7% on placebo (P<0.001 for both doses vs. placebo) [8].

Fibrosis improvement by at least one stage occurred in 24.2% of the 80 mg group and 25.9% of the 100 mg group, vs. 14.2% for placebo [8]. These are the first positive fibrosis endpoints in a Phase 3 MASH trial. No prior drug candidate had cleared this bar.

Resmetirom works by selectively activating thyroid hormone receptor beta (THR-beta) in the liver. This mechanism reduces hepatic fat, lowers atherogenic lipoproteins, and decreases markers of liver inflammation without systemic thyroid effects [9]. In MAESTRO-NASH, LDL cholesterol dropped by approximately 14% in the resmetirom groups compared to a 1% reduction with placebo [8]. Liver fat content measured by MRI-PDFF decreased by a median of 45% to 51% from baseline in the treatment arms [8].

The most common adverse events were diarrhea (occurring in 27% of patients on 100 mg vs. 16% on placebo) and nausea (19% vs. 11%) [8]. These GI side effects were typically mild and concentrated in the first 4 to 8 weeks of therapy, with most patients tolerating continued treatment.

How to Reduce Your Rezdiffra Cost in Utah

Start with insurance. If you carry commercial coverage, confirm that your plan includes Rezdiffra on its formulary (even if on a specialty tier). Have your physician submit prior authorization with fibrosis staging documentation. Once approved, activate the Madrigal savings card to eliminate remaining copays.

If your plan denies coverage, file a formal appeal. Include your biopsy or FibroScan results, your ALT trend over the prior 12 months, and a letter of medical necessity from your hepatologist or gastroenterologist. The AASLD practice guidance on MASH supports pharmacotherapy for patients with stage F2 or higher fibrosis and can strengthen your appeal [10].

For uninsured patients, contact Madrigal's patient assistance program directly. Income-qualified patients may receive Rezdiffra at no cost. Utah also has the Utah Health Insurance Marketplace, where ACA-compliant plans that may cover Rezdiffra are available during open enrollment (November 1 through January 15).

If cost remains prohibitive, discuss alternative approaches with your physician. Weight loss of 10% or more through sustained caloric restriction and exercise has demonstrated histological improvement in MASH, including fibrosis regression, in trials such as the Cuban NAFLD study (N=293), where 10% weight loss produced MASH resolution in 90% of participants [11]. GLP-1 receptor agonists like semaglutide also show hepatic benefit, though they do not yet carry an FDA-approved MASH indication [12]. These are not substitutes for resmetirom in every clinical scenario, but they represent evidence-based options while navigating insurance barriers.